Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Unknown 1Recruiting 1Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Gastrointestinal 3Head & Neck 2Thoracic 1Dermatologic 1

Conditions

Pancreatic Neoplasms 7Prostatic Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Neuroectodermal Tumors, Primitive 2Hypoxia 2Neuroendocrine Tumors 1Neoplasm Metastasis 1Melanoma 1Liver Neoplasms 1Kidney Neoplasms 1Gastrointestinal Stromal Tumors 1Esophageal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 17Surveys and Questionnaires 12Specimen Handling 11Docetaxel 11Nivolumab 9Interviews as Topic 9Standard of Care 8Gemcitabine 8Early Intervention, Educational 8olaparib 7enzalutamide 7Magnetic Resonance Spectroscopy 7Psychiatric Rehabilitation 6Paclitaxel 6durvalumab 5Trastuzumab 5Radiotherapy 5Ipilimumab 5Carboplatin 5Bevacizumab 5pertuzumab 4palbociclib 4cabozantinib 4atezolizumab 4abiraterone 4Therapeutics 4Taxes 4Oxaliplatin 4Methods 4Immunoglobulin G 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Prostatic Neoplasms × TH 302 × Gastrointestinal × Clear all
NCT06782555 2025-01-21

A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab

ImmunoGenesis

Phase 1/2 Recruiting
71 enrolled
GastrointestinalGenitourinaryHead & Neck

Squamous Cell Carcinoma of Head and Neck, Pancreatic Neoplasms, Prostatic Neoplasms

NCT03098160 2017-10-30

Immunotherapy Study of Evofosfamide in Combination With Ipilimumab

Threshold Pharmaceuticals

Phase 1 Unknown
69 enrolled
DermatologicGastrointestinalGenitourinaryHead & Neck

Squamous Cell Carcinoma of Head and Neck, Hypoxia, Melanoma, Pancreatic Neoplasms, Prostatic Neoplasms

NCT00743379 2015-05-07

Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors

Threshold Pharmaceuticals

Phase 1/2 Completed
71 enrolled
GastrointestinalGenitourinaryThoracic

Hypoxia, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡